MedPath

Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Phase 1
Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
First Posted Date
2015-06-25
Last Posted Date
2017-09-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
112
Registration Number
NCT02480894
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

First Posted Date
2015-06-19
Last Posted Date
2023-06-22
Lead Sponsor
SEARCH Research Foundation
Target Recruit Count
15
Registration Number
NCT02475915
Locations
🇹🇭

SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

Phase 1
Completed
Conditions
HIV/AIDS
Interventions
First Posted Date
2015-01-26
Last Posted Date
2017-09-08
Lead Sponsor
International Partnership for Microbicides, Inc.
Target Recruit Count
19
Registration Number
NCT02346084
Locations
🇺🇸

Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

Not Applicable
Terminated
Conditions
HIV
Interventions
First Posted Date
2015-01-07
Last Posted Date
2018-01-19
Lead Sponsor
Emory University
Target Recruit Count
4
Registration Number
NCT02333045
Locations
🇺🇸

Grady Infectious Diseases Clinic (Ponce Clinic), Atlanta, Georgia, United States

🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Phase 2
Completed
Conditions
Acute Leukemia
Chronic Myelogenous Leukemia
Myelodysplasia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell
Lymphoma, Follicular
Hodgkin's Lymphoma
Interventions
First Posted Date
2014-08-04
Last Posted Date
2019-01-23
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
279
Registration Number
NCT02208037
Locations
🇺🇸

University of Florida College of Medicine (Shands), Gainesville, Florida, United States

🇺🇸

Virginia Commonwealth University MCV Hospitals, Richmond, Virginia, United States

🇺🇸

University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States

and more 27 locations

Maraviroc as GVHD Prophylaxis in Transplant Recipients

Phase 1
Terminated
Conditions
Diagnoses That Require Stem Cell Transplant
Graft Versus Host Disease (GVHD)
Interventions
First Posted Date
2014-06-19
Last Posted Date
2020-03-10
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
31
Registration Number
NCT02167451
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Maraviroc and NeuroAIDS Pathogenesis

Phase 2
Completed
Conditions
AIDS Dementia Complex
Interventions
Drug: Placebo
First Posted Date
2014-06-09
Last Posted Date
2021-08-30
Lead Sponsor
University of Hawaii
Target Recruit Count
48
Registration Number
NCT02159027
Locations
🇵🇷

Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico

🇺🇸

Clint Spencer Clinic, Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii, United States

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Not Applicable
Terminated
Conditions
Sarcoidosis
Interventions
Procedure: Bronchoscopy with bronchoalveolar lavage
Procedure: venipunctures
Procedure: Skin biopsy
First Posted Date
2014-05-09
Last Posted Date
2018-02-14
Lead Sponsor
Kevin F. Gibson
Target Recruit Count
3
Registration Number
NCT02134717
Locations
🇺🇸

Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh, Pittsburgh, Pennsylvania, United States

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

Phase 1
Completed
Conditions
Healthy Adult Females
Interventions
First Posted Date
2014-01-17
Last Posted Date
2014-06-19
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
6
Registration Number
NCT02039323
Locations
🇺🇸

CTRC University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

Phase 1
Completed
Conditions
Pharmacokinetics of Maraviroc
Cytochrome P450 CYP3A5 Enzyme Polymorphism
Healthy Subjects
Interventions
First Posted Date
2013-11-08
Last Posted Date
2015-04-06
Lead Sponsor
Johns Hopkins University
Target Recruit Count
24
Registration Number
NCT01980329
Locations
🇺🇸

The Johns Hopkins University School of Medicine Division of Clinical Pharmacology, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy